Recursion is hosting about 60 investors and analysts at its headquarters in Utah. It has generated tons of data with AI and robots, aiming to find a better way to make drugs. Recursion, which has four ...
Recursion's share price has dropped in recent weeks due to poor clinical trial data, but its most mature assets are not reflective of its current capabilities. Recursion probably needs to advance 5-10 ...
Brings together Recursion’s scaled biology exploration and translational capabilities with Exscientia’s precision chemistry design and small molecule automated synthesis capabilities to create a ...
Recursion Pharmaceuticals leverages AI and machine learning to revolutionize drug discovery, reducing costs and accelerating development, positioning itself as a leader in tech-driven biopharma. The ...
Recursion claims that its artificial-intelligence-backed drug discovery platform gets smarter each time it pinpoints a new drug candidate—which is why, even with several of those candidates already in ...
Recursion Pharmaceuticals is merging with Exscientia. The new entity will have the backing of quite a few big names in pharma. It'll also have an even more capable drug discovery and development ...
Some AI-focused companies are not worth the trouble.
Recursion announced the results from its Phase 2 SYCAMORE trial of REC-994, a treatment for Cerebral Cavernous Malformations (CCM), at the International Stroke Conference. The trial met its primary ...
At a job interview on Friday, I had to write code, and one of the things that came up when we were talking about implementation of a concept was recursion. The director of the group said to me "Don't ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results